FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Biotech Enterprise Capital Monitor – USA 09/2023”.
The Monitor is a month-to-month printed overview of enterprise capital traits within the US-Biotech sector.
As of the top of September 2023, we establish the next present VC traits within the US-Biotech sector:
- In 2023, general Biotech funding within the USA has reached USD 15,803m
- In comparison with September 2022 the financing quantity decreased by virtually 38% (25,350m vs. 15,803m)
- The highest 5 offers exceed USD 273m every, the biggest transaction amounted to USD 401m with ElevateBio
- Generate Biomedicines has the best transaction Quantity of USD 273m in September, adopted by ReCode Therapeutics USD 260m and Nimbus Therapeutics USD 210m
- ARCH Enterprise Companions (USA) is main the Prime 5 Buyers (by deal quantity), adopted by Flagship Pioneering (USA) and OrbiMed (USA)
- As a sign oncology information the best funding exercise
To entry the complete report, please click on right here.
By Mathias Klozenbücher, Johannes Hyperlink and Marcel-Louis Christou.